Categories: BionicHealthcareNews

LIAN Group Expands Healthcare Platform with Strategic Acquisition of Scientis, #1 Dermatologist-Recommended Solution for Hyperpigmentation

GENEVA, Aug. 27, 2024 /PRNewswire/ — As part of their Healthcare investment platform, LIAN Group, an innovative investor and operator known for its healthcare investment in the #1 Swiss dentistry network, Cheeze, announces the acquisition of Scientis, a pioneering Swiss Cosmeceutical company. This acquisition strengthens LIAN’s healthcare footprint, as part of their cross-industry investments, focusing on leading solutions that address evolving needs.

Scientis is a Swiss dermatology company dedicated to skin pigmentation with its flagship product Cyspera®. The Cyspera® product line, contains proprietary Cysteamine Isobionic-Amide Complex™ , clinically proven as a pigment corrector. Its unique formula featuring powerful antioxidant properties, positions Cyspera as the first topical product to harness these benefits for uneven skin tone and discoloration. This unique proposition positions the company for global market penetration, with a strong presence already established in Asia and the US.

“We are thrilled to welcome Scientis to LIAN Group’s healthcare platform. We are committed to accelerating Scientis’ growth and sales in new markets by leveraging our network, expertise and resources to expand into new markets, streamline operations, develop innovative products and services, and empower patients and healthcare professionals with high-quality solutions.” says Fiorenzo Manganiello, Managing Partner of LIAN Group.

This acquisition signifies LIAN Group’s commitment to expanding its healthcare platform beyond dentistry as they plan for further acquisitions in the beauty and wellbeing sectors. The LIAN core team will work with Scientis to unlock new markets, optimize operations, and develop new offerings that benefit both patients and healthcare professionals.

About: LIAN Group is a diversified holding group with an “owner and operator” model, fostering innovation and growth across three core platforms: Healthcare, Crypto/Blockchain and AI/Digital Infrastructure. They operate through two models: Venture Studio and Direct Investment, focusing on strategic deals that align with their vision.

Logo – https://healthtechnologynet.com/wp-content/uploads/2024/08/LIAN_Group_Logo.jpg

Media Contact: Erenik Yzeiraj; +41787995758; ey@liangroup.io 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lian-group-expands-healthcare-platform-with-strategic-acquisition-of-scientis-1-dermatologist-recommended-solution-for-hyperpigmentation-302229617.html

SOURCE LIAN Group

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

20 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

20 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

2 days ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

2 days ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

2 days ago